

Immunity to human and bovine respiratory syncytial virus

Brief Review

T. G. Kimman and F. Westenbrink

Central Veterinary Institute, Department of Virology, Lelystad, The Netherlands

Accepted January 17, 1990

Summary. Human and bovine respiratory syncytial viruses resemble each other closely. During annual winter outbreaks, they cause similar respiratory tract disease in infants and calves. The disease is most severe in children and calves between 1 and 3 months old, when maternal antibodies against the virus are usually present. Reinfections, which are common, are accompanied by progressively milder illnesses in children, but are symptomless in calves. Because maternal antibodies suppress serum and mucosal antibody responses of all isotypes, the development of a vaccine that is effective in young children and calves with high levels of maternal antibodies has been severely hampered. Although virus administered intranasally to young calves with maternal antibodies does not evoke antibody responses, it can prime these calves for a protective memory response upon reinfection. Protection appears to be associated with the capacity to mount a mucosal memory IgA response. There are several indications that one or more immunopathologic mechanisms contribute to the disease. An Arthus reaction (type III) may have a role in the pathogenesis, because activated complement may cause most of the pathologic lesions, including edema and emphysema in uninfected parts of the lung. Lungs from calves with severe or fatal disease have depositions of complement component C3 and a low histamine content. The most immunogenic and protective antigen of the virus is the fusion (F) glycoprotein, which evokes a strong antibody response and is a target for cytotoxic T cells. On the F protein, epitopes that induce neutralizing and non-neutralizing antibodies, both of which may enhance complement activation, were identified. Immunity to the F protein may have beneficial and harmful effects.

Introduction

Human respiratory syncytial virus (HuRSV) and bovine respiratory syncytial virus (BRSV) are antigenically closely related and cause similar diseases. To-

gether with pneumonia virus of mice, they belong to the genus *Pneumovirus* of the family *Paramyxoviridae* [73]. HuRSV was discovered in the early 1950s. In the following decades its importance as a major cause of acute lower respiratory tract illness in children, particularly in the first year of life, was established. Infections occur worldwide and show a unique seasonal periodicity [133]. BRSV was first isolated in 1967 by Paccaud and Jacquier [108] in Switzerland. Serological studies in the 1970s and early 1980s clearly established that BRSV is one of the most important respiratory pathogens in older calves and yearlings [50, 131, 154]. Because maternal antibodies interfere with serological studies, BRSV was initially overlooked as a respiratory pathogen of calves younger than three months. When new diagnostic techniques were introduced, BRSV was found to be one of the most frequent and virulent causes of respiratory disease in young calves with maternal antibodies [30, 63, 66, 173]. The severity of HuRSV and BRSV-associated disease seems to be correlated with the level of exposure [42, 43, 46, 80, 121]. Stabling in combination with climatic conditions clearly seem to lead to numerous autumn and winter outbreaks in calves every year in Western Europe. How and where the virus survives between outbreaks is unknown.

Because there is no adequate animal model, progress in understanding the mechanisms of pathogenesis and immunity has been slow. Several species of animals, including calves, cotton rats, ferrets, and mice can be infected experimentally, but only mild clinical and pathological changes or none at all can be induced [27, 65, 112, 138]. Moreover, because the virus grows poorly in cell culture and is extremely labile, it is difficult to obtain large quantities of virus and viral proteins for experimentation. Because passively acquired maternal antibodies are of doubtful protective value, several investigators searched for other, more protective immune mechanisms. Indications for a role of the immune system in the pathogenesis of the disease in humans came from the enhanced disease that occurred when children, immunized with formalin-inactivated vaccine, underwent a subsequent natural infection [24, 85]. Because the vaccine-enhanced disease did not differ from the severe naturally occurring disease, a role of an immune-mediated mechanism was suggested, both in the vaccine-enhanced disease and in the naturally occurring disease. Striking pathological changes in children and calves with naturally occurring infections also suggested that immunological factors influence the development of the lesions [1, 67, 111]. The subject of the present review is the role of the immune system in protection against HuRSV and BRSV infections, as well as its role in the pathogenesis.

Properties of the virus

The genome of HuRSV is a single negative-sense strand of RNA composed of approximately 15,000 nucleotides. It contains one promoter, is transcribed as a single transcriptional unit, and encodes ten mRNAs each coding for a unique

protein. The order of transcription is 3' 1 C-1 B-N-P-M-1 A-G-F-22 k-L 5' [28, 29, 31]. The protein composition of HuRSV and BRSV strains is highly similar, with only minor differences in molecular weight between corresponding proteins [23, 77, 149, 174].

Eight of the ten viral proteins are structural; only proteins 1 B and 1 C are nonstructural. The major glycoprotein (G), the fusion protein (F), and the 1 A protein are glycosylated. They, together with the 22 k protein, are expressed on the cellular membrane [28, 105, 124, 136]. The F protein is synthesized as a 68 k precursor molecule (F₀), which is proteolytically cleaved into disulphide-linked 48 k (F₁) and 20 k (F₂) polypeptide fragments [159]. After proteolytic cleavage, the F protein causes the virus or host cell membrane to fuse with the membrane of uninfected cells. The G protein is the attachment protein of the virus [78]; in contrast to other paramyxoviruses, no hemagglutinin or neuraminidase activity is associated with this protein [123]. The G protein has a protein backbone of approximately 33 k, but due to heavy O-linked glycosylation, it has an apparent weight of 90 k. Arumugham et al. [7] found that a portion of the G protein is linked to the F protein by disulfide bonds. Three proteins, the nucleocapsid protein (N), the phosphoprotein (P), and the large protein (L), constitute, together with the viral RNA, the nucleocapsid of the virus [for reviews, see 28, 133]. The functions of the matrix protein (M), the 22 k, 1 A, 1 B, and 1 C proteins are unknown.

Two broad subgroups (A and B) of HuRSV have been defined based on the reactivity of monoclonal antibodies (MAbs) with various viral proteins. The major antigenic differences between the subgroups are found in the G protein, but differences have also been detected in the F, N, M, and 22 k proteins [4, 39, 92, 114]. The two subgroups do not appear to differ in virulence or in epidemiologic behavior. The prevalence of the HuRSV subgroups varies both during outbreaks and from outbreak to outbreak [49, 94, 152]. There is no evidence that this variation allows reinfections to occur.

BRSV strains share considerable antigenic homogeneity with both HuRSV subgroups, except for the G protein, which is antigenically distinct [77, 107, 139, 149]. It is not clear whether BRSV strains have more than one antigenic type, because only few isolates have been analysed. Although outbreaks of BRSV-associated disease do vary in severity, there is otherwise no indication for clinically relevant strain variation.

Whether bovine isolates can infect humans is unknown. A human isolate, however, has been shown to be pathogenic for calves [56]. Bovine and human isolates both replicate *in vitro* in cells of bovine and human origin, but bovine strains replicate better in bovine than in human cells, whereas for human strains the reverse is true [81].

Viral target antigens

In HuRSV-infected children, antibodies were predominantly induced against the F and N proteins, and, according to some studies, against the G protein [40, 79, 96, 153, 165]. In BRSV-infected calves, the F and N proteins also were

found to be the most immunogenic proteins [174]. In both humans and cattle, antibodies may also be directed against the L, P, M, 22 k, and 1A proteins [79, 101, 165, 174]. The antigenicity of the 1B and 1C proteins is unknown.

Although the sensitivity of the assays used in several studies may be questionable, the G protein appears less immunogenic than the F protein [40, 79, 70, 153, 165, 174]. It has been suggested that the high carbohydrate content (65%) of the G protein may be responsible for the poor immune response [165]. However, Wagner et al. [157, 158] provided evidence that the G and F glycoproteins are both recognized by the human immune system as typical protein antigens, because both proteins elicited primarily IgG1 and IgG3 responses. Carbohydrate antigens primarily elicit IgG2 and IgG4 responses. The G protein is also poorly recognized by cytotoxic and helper T cells [10].

Immunizing mice or cotton rats with vaccinia recombinant viruses (VRV) and with purified proteins demonstrated that the F and G proteins are the major antigens that protect against challenge; these proteins also induce neutralizing antibodies [35, 72, 104, 125, 134, 162, 172]. Animals immunized with VRV that expresses the N protein (VRV-N) were less protected than those immunized with VRV that expresses either the F (VRV-F) or the G (VRV-G) protein [72], and those immunized with VRV-F were better protected than those immunized with VRV-G [104, 135]. Mice and cotton rats immunized with VRV-G that expresses the G protein of subgroup A HuRSV were protected against challenge with subgroup A, but not with subgroup B HuRSV. Those immunized with VRV-F that expresses the F protein of subgroup A HuRSV were protected against infection with either subgroup [135].

Several laboratories have identified four to five antigenic sites on the F protein, three to four of which are involved in neutralization [14, 107, 126, 147, 161]. MAbs that are directed against at least two of the antigenic sites involved in neutralization also inhibit fusion [14]. Using MAb-resistant mutants, several epitopes within the neutralization sites have been identified [14]. A peptide that was defined by amino acids 221–232 within the F₁ region of the F protein was identified as part of the binding site for neutralization and fusion-inhibiting MAbs [148]. The G protein of subtype A contains at least three antigenic sites and the G protein of subtype B at least two. Two of the antigenic sites of subtype A and both antigenic sites of subtype B were neutralizing sites, although not all MAbs directed to these sites neutralized the virus in vitro. One neutralizing site was shared by both subgroups [5, 151, 163]. However, neutralization of the virus is complex, and antibodies directed against different antigenic sites on the F or the G protein can act together to neutralize the virus (from partial or no neutralization to complete neutralization) [6, 163]. Effective neutralization is seen primarily with MAbs against the F protein [4, 136]. Using a series of overlapping synthetic peptides, Nicholas et al. [101] identified an antibody-binding site on the 1A protein (residues 51 through 60) that may be recognized during natural human infection.

Using VRV-G, -N, and -F, it was shown that the N and F proteins are the major antigens recognized by cytotoxic T cells in mice and humans [11, 22, 72,

110] and by helper T cells in mice [106]. The 1A protein is also recognized by helper T cells in mice. The extracellular C-terminal domain of the 1A protein contains two overlapping epitopes which stimulate T helper cells and which can be distinguished by different class II MHC restriction elements [101, 102].

Protective immunity

Reinfections with HuRSV and BRSV occur readily. Children may have severe disease after the second infection with HuRSV, but subsequent infections gradually decrease in severity [48]. This partial protection is somewhat greater against viruses of the same subgroup [93]. HuRSV infection sometimes causes clinical signs of disease in adults [155] and can cause severe disease in the elderly [90]. Reinfected calves do not develop clinical signs of disease. Older cattle that contract primary infections can develop severe disease [55]. Interestingly, BRSV was first isolated from adult cattle with respiratory disease [108].

Antibodies in serum

Several field and laboratory studies of different species have failed to show a clear correlation between the level of actively or passively acquired serum antibodies (usually determined in virus neutralization tests) and protection. Age, species, and quantity of antibodies in serum seems to determine the level of protection [57, 66, 70, 76, 87, 89, 109, 115, 117, 132, 165]. Passive transfer of MAbs directed against the F and G proteins can reduce virus replication in the lungs of mice and cotton rats [115, 136, 139, 160]. MAbs directed against the F protein were more effective in neutralizing the virus in vitro and were more protective in vivo than MAbs directed against the G protein [4, 136, 139]. However, there was no correlation between neutralizing or complement-dependent cytotoxic activity of the passively transferred MAb and its protective effect, which suggests that other mechanisms may also be involved in protection [139]. In addition, not all neutralizing MAbs were protective and non-neutralizing MAbs may provide protection in vivo [139, 163]. Antibodies may act in association with effector cells in antibody-dependent cell-mediated cytotoxicity. Inhibition of cell fusion appears to be essential for the protective effect of MAbs directed against the F protein [136]. MAbs directed against the N protein did not protect [139]. Passively transferred antibodies that restrict virus replication in the lung have only a slight effect on virus replication in the nose [160, 175]. This suggests that the close contact between blood and alveolar lumina allows passive diffusion of protective serum IgG into the deeper airways, while the upper respiratory tract remains unprotected. Whether the observations made in mice and cotton rats can be extended to the natural hosts of HuRSV and BRSV is questionable. Reportedly, experiments are being conducted that will establish the protective capacity of neutralizing bovine MAbs directed against the F protein in calves [60].

Maternal antibodies

Both in infants and calves, maternal antibodies are universal, probably as a result of frequent reinfections in older individuals. Hornsleth et al. [51] determined that maternal antibody in children was entirely of the IgG1 isotype, although theoretically some IgG3 might have been present. Murphy et al. [96, 97] and Levine et al. [79] found that maternal antibodies of infants react with the F and G proteins. In calves, maternal antibodies are of the IgG1 isotype, they are only found in serum, and they have a half-life of 23 days. They are not actively transported to mucosal surfaces. Maternal antibodies of calves are predominantly directed against the F and N proteins [64, 65, 174]. Some calves also have maternal antibodies against the G protein. Calves, in contrast to humans, acquire maternal antibodies only via colostrum.

Maternal antibodies suppress serum and mucosal antibody responses of all isotypes, despite extensive replication of the virus. In calves, the IgM responses appeared the least sensitive to suppression [65, 173]. Murphy et al. [97] demonstrated that maternal antibodies may cause poor and irregular responses against the F and G proteins even in children as old as 8 months. Although the antibody response to whole virus is strongly inhibited by maternal antibodies, responses to individual viral proteins, notably the F and P proteins, can sometimes be detected [70, 79, 174]. In cotton rats, antibody responses to VRV-expressed F and G proteins were suppressed by passively transferred HuRSV immune serum, but antibody responses to the vaccinia virus antigens were not [98]. Bangham [10] demonstrated that passively acquired antibody in newborn mice may not only impair the antibody response but also the generation of specific cytotoxic T cell precursors.

Although maternal antibodies play a crucial role in regulating the antibody response in young animals, remarkably little research has been done on this subject. In our studies, immunization via the respiratory tract did not prevent the priming for memory responses in calves with maternal antibodies [65, 70]. Thus, maternal antibodies did not completely prevent the processing of antigen, the recognition of antigen by B and T cells, or the induction of certain memory cells. Maternal antibodies may interfere with the forming of antibody-secreting B cells, possibly via suppressor or helper T cells [47, 120]. Other mechanisms may be the limiting of virus replication, the enhanced clearance of antigen, and idiotype interactions.

The immaturity of the immune system might also impair the immune response in young children [96, 109]. There are no indications that age affects the immune response of calves [65, 133].

The influence of maternal antibody on the outcome of disease

The influence of age and maternal antibodies on infection in young infants and calves has been investigated in several studies, but the results have often been conflicting [8, 45, 61, 65, 66, 76, 86, 89, 103, 165]. In hospitalized infants, the

severity of disease peaks in the second month of life, when maternal antibody is still universal [109]. In hospitalized children with severe disease there is no correlation between serum antibody level and severity of disease [15, 109]. There is, on the other hand, evidence that maternal antibody may provide some, yet incomplete, protection. Infants less than 3 weeks old, who have the highest levels of maternal antibody, are relatively spared from severe disease. Maternal antibody reduces virus shedding, and there is a correlation between the level of neutralizing maternal antibody at birth and the age at the time of infection [24, 44, 45, 76, 103, 165]. Ward et al. [165] found that a high level of maternal antibody directed against the N protein was associated with protection against disease.

During the seasonal circulation of the virus among cattle, disease can frequently be observed in calves of 2 weeks old and older. Most cases of severe disease develop in calves from 1 to 3 months old, nearly all of which still have maternal antibody [66]. However, both the incidence and severity of disease in calves younger than 3 months were inversely related to the level of BRSV maternal antibodies. Thus, under field conditions, maternal antibodies do not effectively prevent BRSV-associated disease, but they do appear to mitigate it [66]. Under experimental conditions, calves with maternal antibodies can easily be infected [65, 89]. In newborn cotton rats, antibodies acquired via the placenta and from breast milk reduced the replication of virus in the lungs, but not in the nose [175].

Because most severe disease occurs both in calves and in children when maternal antibodies are present, it has been suggested that these antibodies may aggravate disease by an antigen – antibody reaction [66, 103]. Perhaps the ratio between antibodies directed against protective and nonprotective epitopes is a factor that determines the severity of disease (see below). Murphy et al. [98] found that in cotton rats the antibody response to neutralizing epitopes on the F protein was disproportionately more suppressed by passively transferred hyperimmune serum than the response to nonneutralizing epitopes on the same protein. Alternative explanations for the severe disease in children and calves with maternal antibodies may be that young age as such predisposes to severe disease, or that maternal antibodies suppress the immune response needed to clear the infection. No support was found for the latter possibility, however, after experimentally induced infection in calves [65, 70], but cotton rats, whose immune response were suppressed by passively transferred antibodies, were more susceptible to infection than control animals [98]. Both calves and infants can recover from infection without any detectable serum or secretory antibody response [64, 65, 83].

Some epidemiologic studies of HuRSV have suggested that breast feeding has a beneficial effect on infections, although conflicting evidence has also been reported [33, 42, 119, 137]. The possible protective mechanism of breast-feeding has not been identified with certainty, but may be related to interferon [25, 100, 133]. Colostrum and milk further contain abundant IgA, some of which

is HuRSV-specific and which may be excreted in nasal secretions of the newborn. HuRSV reactive lymphocytes are present in the colostrum of 30–40% of mothers [33, 129], but their significance is doubtful.

Antibodies at mucosae

Evidence for a beneficial effect of mucosal IgA in HuRSV infections is limited. The appearance of specific IgA and the disappearance of virus after the first infection were closely related in time [83, 84]. However, calves with maternal antibodies, which had completely suppressed mucosal IgA responses, did not shed virus any longer than calves without maternal antibodies [65]. Moreover, children that do not have a secretory antibody response because of suppressive maternal antibody can normally recover from infection [83]. In adult volunteers, resistance to infection and illness appeared to be correlated with high levels of neutralizing antibody in nasal wash at the moment of infection, but not with the level of neutralizing antibody in serum [88].

We studied the mucosal antibody response of calves in detail [64, 65, 70]. BRSV-specific IgM appeared 8–10 days after a primary infection in blood, and in samples collected from the eye, nose, lungs, and even the intestine; shortly afterward, IgA appeared [65]. The antibodies remained detectable for various lengths of time. BRSV-specific IgG1 and IgG2 appeared later and were only detected in serum. In maternally immune calves, antibody responses were undetectable or detectable only for short periods and at low titers. All calves, with or without maternal antibodies, excreted virus in about equal amounts and for the same period of time. After reinfection, 3 to 4 months later, memory responses were observed in serum and on the mucosae in calves with or without maternal antibodies. Memory responses were characterized by strong and rapid increases (from day 6 after inoculation) in mucosal and serum IgA as well as increases in serum IgG1 and IgG2. Also, strong mucosal, but not serum, IgM responses were observed, but they did not develop faster than they did after primary infection. Memory responses were even detected in calves that had not developed an antibody response after the primary infection. Maternal antibodies, present at the time of priming, adversely affected the maximum antibody titers after challenge, either because priming was inefficient or because the immune response continued to be suppressed. After reinfection, none of the calves, with or without maternal antibodies at the time of priming, excreted virus.

Virus administered intramuscularly to seronegative calves failed to induce a mucosal antibody response, but did prime for a mucosal memory response [70]. This finding indicates that immune cells circulate, before or after challenge, from peripheral lymph nodes to the mucosae, as well as circulating between the mucosae. The memory response in intramuscularly immunized calves, however, started somewhat later than in calves primed intranasally and did not prevent virus excretion. Because virus excretion peaks on day 5 or 6 after inoculation [65, 70], rapidity of the IgA memory response may be im-

portant for protection. The mucosal memory response may be more rapid after intranasal priming because local memory cells are activated. Parenteral immunization may be effective because it primes for mucosal memory. In the same study, seronegative calves were immunized with inactivated virus via the respiratory tract and maternally immune calves were immunized with live virus intramuscularly. These calves were the least effectively primed for mucosal memory and also excreted virus after challenge [70]. The following conclusions were drawn [70]:

- Protection against virus excretion was not so much associated with the presence of IgA on the mucosae at the time of challenge, as with the capacity to mount a mucosal memory response. The presence of local IgA does indicate that the mucosae have been primed; but even when local IgA is not present, mucosae may still be primed.

- Intranasal immunization with live virus can prime the mucosae of calves (even those with maternal antibodies) for antibody memory responses.

- Intramuscular immunization with live virus, which probably results in limited replication of virus at the site of inoculation [75, 113, 176], can prime mucosae, but the memory response after challenge appeared somewhat delayed and did not prevent virus excretion.

- In contrast with intranasal immunization, intramuscular immunization with live virus did not prime for mucosal memory in calves with maternal antibodies.

We could not conclude whether IgA alone protects, or whether other mechanisms, such as cytotoxic T cells or killer cells, work in conjunction with it. Mazanec et al. [82] has demonstrated that monoclonal IgA directed against neutralizing epitopes on the haemagglutinin-neuraminidase molecule of Sendai virus protected mice against the virus when administered to the respiratory tract. We and others could not demonstrate neutralizing activity of IgA, which may reflect low avidity or differences in the sensitivity of the assays [64, 83]. IgA may be active in antibody-dependent cell-mediated cytotoxicity, but probably plays no role in complement-mediated cell lysis [69].

T cell-mediated immunity

Little is known about the role of T cells in the recovery from and protection against disease. Proliferating T cell responses have been detected after infection of calves and infants [128, 141], but their function and role in protection is unknown. Virus-specific MHC-restricted cytotoxic T cells have been detected in mice, cotton rats, and humans [9, 10, 75, 140]; helper T cells have been detected in mice [106]. Murine helper and cytotoxic T cells appear to be partly subgroup-specific [12, 22, 106, 110]. Non MHC-restricted natural cytotoxicity has been detected in cotton rats [75]. T cells seem to be beneficial because infants and mice with a defective cell-mediated immune response are unable to eliminate a HuRSV infection [37, 140]. Moreover, immunization with VRV-N limits virus replication in cotton rats [72]. Transfer of primed T cells can

clear persistent HuRSV infection in immunodeficient mice [20, 110]. Transfer of specific cytotoxic T cell lines and clones into infected mice also resulted in virus clearance, but was associated with a lethal respiratory disease, characterized by hemorrhage and neutrophil influx [21]. It is unclear whether this phenomenon has anything to do with naturally occurring disease.

Role of immunity in pathogenesis

The role of immune mechanisms in the pathogenesis of HuRSV disease has been the subject of numerous studies [133, 170]. These studies were spurred not only by the high incidence of severe disease in children with maternal antibodies, but also because formalin-inactivated vaccine actually enhanced the disease. Evidence has been provided that formalin destroys epitopes that bind neutralizing and fusion-inhibiting antibodies on the F or G protein or both [95, 99, 116]. Formalin-inactivated vaccine induces predominantly “non-functional” antibodies, which can bind virus, but cannot neutralize infectivity or inhibit cell fusion. “Non-functional” antibodies present at the time of infection or acceleratively produced after infection, may enhance disease by causing an Arthus reaction (type III). The role of these antibodies in complement activation or in complement-mediated cytotoxicity was, however, not examined. The F protein in particular seems capable of inducing “non-functional” antibodies [14, 125]. Some MAbs that are directed against the F protein and neutralize a given strain bind to other strains, but fail to neutralize them [14]. Prince et al. [116] enhanced the disease in cotton rats by using formalin-inactivated vaccine and found histologic evidence for an Arthus reaction 24 h after challenge. A second influx of neutrophils and lymphocytes 4 days after challenge suggested that also a delayed type hypersensitivity reaction (type IV) may develop.

Some clinical findings suggest that antibody is also involved in the pathogenesis of BRSV disease in calves. Calves with maternal antibodies have a high frequency of severe disease [66, 133]. Severe disease also occurs, however, in older calves that are seronegative at time of infection. These calves show the characteristic abdominal breathing just before a vigorous IgM, IgG1 and IgA response can be measured. At that time, low levels of neutralizing antibodies can already be detected [50, 64, 67, 111, 166]. Thus, if disease is indeed enhanced by antigen – antibody interaction, this may occur at low antibody levels. There are no indications for prior sensitizing infections, because only calves that have not been exposed to earlier periods of virus circulation become ill [50, 154]. One case of naturally occurring BRSV infection indicated that vaccination with modified live vaccine during the infection may have also enhanced the severity of disease [71].

Welliver et al. [169] have postulated that an anaphylactic hypersensitivity reaction (type I) may develop in children with HuRSV infections. Anaphylaxis is mediated by cytophilic antibodies on mast cells, which degranulate on binding of antigen. They assumed that a defect in the suppressor cells may lead to

uncontrolled IgE synthesis, mast cell degranulation, and bronchoconstriction. Two groups of investigators found an association between early and high anti-HuRSV IgE antibody levels in secretions and serum and the severity of lower respiratory tract disease [17, 169, 170]. However, not all children hospitalized for a HuRSV infection have detectable antiviral IgE [169, 171], and it is questionable whether IgE actually reaches high levels in the early stages of primary infection. Unfortunately, virus-specific IgE assays have been difficult to develop, and their results have not been confirmed in other laboratories [144].

In cattle, anaphylaxis can be mediated by IgG1 and probably also by IgE [19, 142]. Stewart and Gershwin [130] failed to find a clear correlation between BRSV-specific IgE concentration in serum and clinical signs of disease after experimentally induced infection. They noted that, in contrast to the naturally occurring situation, clinical signs of disease after primary and secondary infections were similar. This finding suggests that hypersensitivity to cell culture components might have occurred. Unfortunately, IgE responses have not yet been examined in calves with severe natural disease.

Antibody may possibly also enhance disease by facilitating the infection of monocytes and macrophages. Antibody may bind with the virus and then bring the virus in contact with Fc receptors on these cells [41, 74]. The Fc receptor-bearing cells are not the primary target cells of HuRSV, but these cells can be infected *in vitro*, and HuRSV antigen has been found in circulating monocytes after naturally occurring infections [32, 74]. When cells bearing Fc receptors become infected or interact with the virus, they may release leukotrienes and platelet-activating factor, which could induce bronchoconstriction [36, 146].

It has also been proposed that a cell-mediated immune reaction might contribute to the pathogenesis of the disease, but firm evidence was not provided [62, 167].

Lesions

In naturally infected calves with respiratory distress or that succumbed, severe lesions were observed: consolidation of the cranioventral (CV) lung, severe edema and emphysema throughout the lung, and signs of severe dyspnea, such as cyanosis and widespread hemorrhages [67, 111]. The emphysema appears to be caused by widespread bronchoconstriction. The edema and emphysema likely cause the severe dyspnea. Hyaline membranes accompanied by lung parenchymal necrosis were often detected in both the CV and caudodorsal (CD) lung. The virus, however, was only detected in the CV lung [67]. Thus, a major question is what causes the severe changes in blood vessels and smooth muscles in parts of the lung where no virus is detected? In the CV lung, viral cytopathologic changes were detected in bronchiolar and alveolar epithelium and were accompanied by inflammation. Some few eosinophilic leukocytes were found in both the CV and CD lung. Dyspnea probably develops late in the infection: it usually lasted only a short time, whereas the inflammation in the

CV lung often already had chronic characteristics, such as epithelial hyperplasia, fibrosis, and bronchiolitis obliterans. In addition, all calves that died or were killed during severe dyspnea had antiviral IgG 1 or IgM or both [67]. These antibodies were directed against the same viral proteins as antibodies of calves that recovered [174]. BRSV-specific IgA was usually not detected, either in serum or in lung lavage fluid. Whether the absence of specific IgA is an immunologic defect is unknown. A deficiency in IgA has also been reported in children with fatal infections [3]. Chronic lesions may develop in calves because it takes time to produce sufficient viral antigen or antibody or both to initiate an immune-mediated reaction. Sometimes two stages of disease are observed shortly after each other, which may be in agreement with this suggestion [8, 50]. Because a few very young calves had only acute bronchiolar lesions [67], severe disease may develop earlier in calves with high levels of maternal antibodies. The lesions detected in the CV lung of calves closely resemble those in infants with fatal HuRSV disease [1]. Widespread alveolar lesions in parts of the lungs that are not infected have not been reported in children, however.

Complement component 3 (C3) was detected in the CV lung, but although antigen and antibody were both present, immune complexes were not found [68]. Fixation of C3 to exfoliated airway epithelial cells was also found in children with HuRSV infection [58]. A low histamine content of both the CV and CD lung, together with small numbers of mast cells and mast cell granules, indicated mast cell degranulation [68]. Complement and mast cell activation are probably linked, because activated complement components C3a and C5a (anaphylatoxins) are known to liberate histamine and other mast cell mediators. Virus infections can probably further enhance the release of histamine through interferon [18, 54]. Evidence has been provided that several secondary mediator systems are recruited by anaphylatoxins, including vasoamines, prostaglandins and leukotrienes. The activity of these mediators is synergistic. In nasopharyngeal samples from HuRSV-infected infants leukotriene C4 has been demonstrated [156]. Anaphylatoxins enhance vascular permeability, smooth muscle contraction, and chemotactic attraction of neutrophils. Anaphylatoxins can mediate acute, often fatal, lung injury, after either intravascular or intrabronchial instillation. Characteristics of the response are prolonged bronchospasm, hyperinflation of the lungs, increased vasopermeability, and cellular infiltration [52, 53].

In conclusion, the extent to which the virus itself, complement, mast cell mediators, or other mechanisms contribute to the final disease is unclear. Anaphylaxis and delayed type hypersensitivity might be involved in the pathogenesis but these mechanisms do not explain the widespread lesions and mast cell degranulation detected even in the absence of antigen; there are no histological indications for delayed type hypersensitivity. We may postulate an important role for an Arthus reaction, because activated complement would explain the following findings:

- pulmonary edema and emphysema,

- lesions outside the focus of infection, assuming circulation of activated complement components,
- aggravation of disease by IgG1 or IgM. This would also explain the severe disease in advanced stages of infection when chronic lesions and antibodies are present.
- severe disease thanks to the amplification loop of the alternative pathway of complement,
- release of mast cell mediators,
- neutrophil influx in infected parts of the lung.

Activation of complement

In the absence of antibody, HuRSV- and BRSV-infected cells activate more complement than uninfected cells. Antibodies increase complement activation and cooperation of antibody and complement is required to induce complement-mediated lysis [59, 69]. In a homologous bovine system, complement activation was enhanced by specific IgG1 and IgM, but not by IgA and IgG2. Antibody-enhanced complement activation was largely mediated by the alternative pathway and caused cell lysis [69]. Murine MAbs directed against neutralizing and non-neutralizing epitopes on the F protein can also enhance complement activation. One MAb of the IgG1 isotype and directed against a non-neutralizing epitope on the F protein enhanced C3 binding to infected cells, but did not induce complement-mediated lysis [69]. Thus, IgG1 or IgM antibodies directed against this epitope may activate the adverse inflammatory effects of the complement system without inducing beneficial lysis and without neutralizing the virus. Once more is known about epitopes that induce protective or non-protective responses, it would be worthwhile to measure epitope-specific immune responses. Individuals may respond differently to different epitopes, as demonstrated for hemagglutinin of influenza virus [164].

Whether antibodies directed against other surface proteins (i.e., the G, 22 k, and 1A proteins) can also enhance complement activation is unknown. During the acute stages of the disease, however, anti-G antibodies are probably not important in activating complement. The G protein seems less immunogenic and antibodies against the G protein were usually not detected in sera of calves collected during the acute phase or postmortem [174].

Besides having an inflammatory effect, complement activation may also help in recovery from the disease. Complement activation, whether in the presence or absence of antibody, may lead to the interaction of neutrophils bearing complement receptors with infected cells and thus cause the destruction of these cells [59].

Role of antibodies in diagnosis

The standard method of diagnosing HuRSV infections is to isolate virus in cell culture. Nasal washes give more successful results than nasal or throat swabs, or tracheal aspirates [145]. Because antiviral therapy requires a more rapid

diagnosis than is possible with cell culture, several groups developed methods for rapid identification of viral antigen by immunoassay [2, 26, 38, 170]. The specificity and sensitivity of these assays is usually good, and antigen may even be identified in samples that are negative in cell culture. Attempts to isolate virus from nose swabs collected from calves has rarely been successful [16, 34, 111, 143, 166], perhaps because the virus mainly replicates in the lung [67]. Detecting virus or viral antigen in material collected by lung lavage has improved BRSV diagnosis, especially in calves with maternal antibodies [63].

Because of suppressive maternal antibody, classic serodiagnostic techniques are quite insensitive for diagnosing infection in infants and calves younger than 3 months [66, 122, 127, 168]. Some maternally immune children and calves that do not have an increase in serum IgG level upon infection maintain IgG titers for several months [103, 173]. Although IgA and IgM responses confirmed infection, maintained IgG titers do not seem feasible for routine diagnostic use. In a small study of infants from 1 to 3 months old, increases were more often detected in IgG3 antibodies than in IgG1 antibodies [51]. This finding indicates that IgG3 may be valuable in diagnostics, although it has only a brief half life (seven days).

Detecting specific serum IgM proved to be useful in diagnosing infection in calves with and without maternal antibodies [66, 173]. In calves older than 3 months from herds with BRSV-associated disease, 80 per cent showed an increase in IgG titer in paired sera against BRSV and 77 per cent had specific serum IgM. In contrast, only 10 per cent of the calves younger than 3 months showed an increase in IgG titers, while 51 per cent had specific IgM. In calves older than 3 months, BRSV-specific IgM was detected for 12 to 37 days [66]. However, sampling in the acute stage of disease may be too early, and in calves younger than 3 months, the IgM response may be so short-lived that it is easily missed [65, 173]. HuRSV-specific IgM responses have also been evaluated for the diagnosis of acute infection in humans. Though easily detected in infants of more than 3 months, IgM was only found in a minority of HuRSV-infected children between 1 and 3 months [170, 171]. More frequent sampling may increase the detecting of IgM responses in this age group. Specific IgA has not been evaluated for diagnostic use on a large scale [65, 96]. For diagnosing infection in calves, specific IgM has appeared to be superior to IgA, although this finding may be the result of different sensitivities of the assays [65].

Epilogue

An effective and safe vaccine that can be administered to very young children and calves with high levels of maternal antibodies is clearly needed. The live attenuated vaccines available for calves are ineffective in calves with maternal antibodies. The WHO has given high priority to the development of a HuRSV vaccine [118]. The lack of a good laboratory animal model severely hampers vaccine development, as it does the study of the pathogenesis. If continued

efforts to improve animal models fail, vaccine candidates should be tested in cotton rats, calves, or nonhuman primates before being tested in the field; virus contents of lungs or lung lavage fluid and the development of lesions can be used as parameters to measure protection. Because naturally infections do not induce protection against reinfection in either humans or cattle [50, 88, 132], attempting to prevent infection by vaccination is probably unrealistic. The goal of vaccination must therefore be to prevent clinical disease. A live vaccine administered intranasally may give the best results. Mucosal immunization not only seems more effective than parenteral immunization, it may also be effective in the presence of maternal antibody, and leads to IgA antibodies, which are less likely to contribute to immune-mediated pathogenesis than IgG1 or IgM. Recombinant DNA technology may be able to create such a vaccine, but classical methods of vaccine development should not be neglected. Another possibility, at least in cattle, is the use of inactivated antigen in an immunogenic form and in combination with an adjuvant. Examples are immunostimulating complexes (ISCOMs), made from viral surface proteins absorbed to the adjuvant Quil A, and glutaraldehyde-fixed infected cells [132, 150].

Vaccine may be developed by constructing a vector organism that expresses one or more antigens of the virus. Candidate antigens are not only the F and G proteins, which have been shown to be important for protection, but also the N protein. The N protein has been shown to afford a significant degree of protection against HuRSV in mice and has also been demonstrated to be a target protein for murine and human cytotoxic T cells [13, 35, 72, 104, 125, 135, 139]. The safety of such a vaccine may be a problem, because the F and G proteins might alter host and tissue tropism of the vector and virulence [135]. Recombination with wild-type variants of the vector may be another risk. Vaccine may also be developed by the introduction of (small) deletions or mutations in the genome to reduce the virulence of the virus without losing its protective ability. Such an approach might also establish the function of viral structures [91]. Because the F protein functions both in protection and pathogenesis (fusing cells and mediating complement activation), it would particularly be interesting to examine the effect of specific deletions or mutations in the F gene. Mutations that decrease the cleavability of the F protein might decrease virulence. Deletion of one or more non-neutralizing epitopes, which in particular are suspected to participate in immunopathology, might also decrease virulence.

Acknowledgements

We thank Dr. J. G. van Bekkum and Dr. C. Terpstra for critical comment and Victoria Thatcher for editing the manuscript.

References

1. Aherne W, Bird T, Court SDM, Gardner PS, McQuillin J (1970) Pathological changes in virus infections of the lower respiratory tract in children. *J Clin Pathol* 23: 7–18

2. Ahluwalia G, Embree J, McNicoll P, Law B, Hammond GW (1987) Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. *J Clin Microbiol* 25: 763–767
3. Aiuti F, d'Amelio R, Palmisano L, Valesini G, Luzi G, Giunchi G (1980) IgA deficiency and circulating immune complexes in Neapolitan children with fatal acute respiratory infections. *Lancet* ii: 226–229
4. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K (1985) Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. *J Infect Dis* 151: 626–633
5. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Fernie BF (1986) Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. *J Clin Microbiol* 23: 475–480
6. Anderson LJ, Bingham P, Hierholzer JC (1988) Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. *J Virol* 62: 4232–4238
7. Arumugham RG, Hildreth SW, Paradiso PR (1989) Interprotein disulphide bonding between F and G glycoproteins of human respiratory syncytial virus. *Arch Virol* 105: 65–79
8. Baker JC, Ames TR, Markham RJF (1986) Seroepizootiological study of bovine respiratory syncytial virus in a herd. *Am J Vet Res* 47: 240–245
9. Bangham CRM, Cannon MJ, Karzon DT, Askonas BA (1985) Cytotoxic T-cell response to respiratory syncytial virus in mice. *J Virol* 56: 55–59
10. Bangham CRM (1986) Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. *Immunology* 59: 37–41
11. Bangham CRM, McMichael AJ (1986) Specific cytotoxic T cells recognize B cell lines persistently infected with respiratory syncytial virus. *Proc Natl Acad Sci USA* 83: 9183–9187
12. Bangham CRM, Askonas BA (1986) Murine cytotoxic T cells specific to respiratory syncytial virus recognize different antigenic subtypes of the virus. *J Gen Virol* 67: 623–629
13. Bangham CRM, Openshaw PJM, Ball LA, King AMQ, Wertz GW, Askonas BA (1986) Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. *J Immunol* 137: 3973–3977
14. Beeler JA, van Wyke Coeling K (1989) Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. *J Virol* 63: 2941–2950
15. Bruhn FW, Yeager AS (1977) Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection. *Am J Dis Child* 131: 145–148
16. Bryson DG, McFerran JB, Ball HJ, Neill SD (1979) Observations on outbreaks of respiratory disease in calves associated with parainfluenza type 3 virus and respiratory syncytial virus infection. *Vet Rec* 104: 45–49
17. Bui RHD, Molinaro GA, Kettering JD, Heiner DC, Imagawa DT, Geme JWS (1987) Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus. *J Pediatr* 110: 87–90
18. Busse WW, Swenson CA, Borden EC, Treuhaft MW, Dick EC (1983) Effect of influenza A virus on leukocyte histamine release. *J Allergy Clin Immunol* 71: 382–388
19. Butler JE (1983) Bovine immunoglobulins: an augmented review. *Vet Immunol Immunopathol* 4: 43–152

20. Cannon MJ, Stott EJ, Taylor G, Askonas BA (1987) Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. *Immunology* 62: 133–138
21. Cannon MJ, Openshaw PJ, Askonas BA (1988) Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. *J Exp Med* 168: 1163–1168
22. Cannon MJ, Bangham CRM (1989) Recognition of respiratory syncytial virus fusion protein by mouse cytotoxic T cell clones and a human cytotoxic T cell line. *J Gen Virol* 70: 79–87
23. Cash P, Wunner WH, Pringle CR (1977) A comparison of the polypeptides of human and bovine respiratory syncytial viruses and murine pneumonia virus. *Virology* 82: 369–397
24. Chanock RM, Kapikian AZ, Mills J, Kim HW, Parrott RH (1970) Influence of immunological factors in respiratory syncytial virus disease. *Arch Environ Health* 21: 347–356
25. Chiba Y, Minagawa T, Mito K, Nakane A, Suga K, Honjo T, Nakao T (1987) Effect of breast feeding on responses of interferon and virus-specific lymphocyte transformation in infants with respiratory syncytial virus infection. *J Med Virol* 21: 7–14
26. Chonmaitree T, Bessette-Henderson BJ, Hepler RE, Lucia HL (1987) Comparison of three rapid diagnostic techniques for detection of respiratory syncytial virus from nasal wash specimens. *J Clin Microbiol* 325: 740–747
27. Coates HV, Chanock RM (1962) Experimental infection with respiratory syncytial virus in several species of animals. *Am J Hyg* 76: 302–312
28. Collins PL, Wertz GW (1986) Human respiratory syncytial virus genome and gene products. In: Notkins AL, Oldstone MBA (eds) *Concepts in viral pathogenesis*, vol 2. Springer, Berlin Heidelberg New York Tokyo, pp 40–46
29. Collins PL, Dickens LE, Buckler-White A, Olmsted RA, Spriggs MK, Camargo E, Coelingh KVV (1986) Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. *Proc Natl Acad Sci USA* 83: 4594–4598
30. De Leeuw PW, Kamp EM, Kimman TG, Ter Laak EA, Straver PJ, Zimmer GM (1984) Luchtwegaandoeningen bij kalveren. In: Annual report, Central Veterinary Institute, Lelystad, The Netherlands, pp 13–18
31. Dickens LE, Collins PL, Wertz GW (1984) Transcriptional mapping of human respiratory syncytial virus. *J Virol* 52: 364–369
32. Domurat F, Roberts NJ, Walsh EE, Dagan R (1985) Respiratory syncytial virus infection of human mononuclear leukocytes in vitro and in vivo. *J Infect Dis* 152: 895–902
33. Downham MAPS, Scott R, Sims DG, Webb JKG, Gardner PS (1976) Breast-feeding protects against respiratory syncytial virus infections. *Br Med J* 2: 274–276
34. Edwards S, Newman RH, Stanley M (1984) Respiratory syncytial virus diagnosis. *Vet Rec* 114: 101
35. Elango N, Prince GA, Murphy BR, Venkatesan S, Chanock RM, Moss BA (1986) Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. *Proc Natl Acad Sci USA* 83: 1906–1910
36. Faden H, Hong JJ, Ogra PL (1984) Interaction of polymorphonuclear leukocytes and viruses in humans: adherence of polymorphonuclear leukocytes to respiratory syncytial virus-infected cells. *J Virol* 52: 16–23
37. Fishaut M, Tubergen D, McIntosh K (1980) Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. *J Pediatr* 96: 179–186

38. Freymuth F, Quibriac M, Petitjean J, Amiel ML, Pothier P, Denis A, Duhamel JF (1986) Comparison of two new tests for rapid diagnosis of respiratory syncytial virus infections by enzyme-linked immunosorbent assay and immunofluorescent techniques. *J Clin Microbiol* 24: 1013–1016
39. Gimenez HB, Hardman N, Keir HM, Cash P (1986) Antigenic variation between human respiratory syncytial virus isolates. *J Gen Virol* 67: 863–870
40. Gimenez HB, Keir HM, Cash P (1987) Immunoblot analysis of the human antibody response to respiratory syncytial virus infection. *J Gen Virol* 68: 1267–1275
41. Gimenez HB, Keir HM, Cash P (1989) In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera. *J Gen Virol* 70: 89–96
42. Glezen WP, Denny FW (1973) Epidemiology of acute lower respiratory disease in children. *New Eng J Med* 288: 498–505
43. Glezen WP (1977) Pathogenesis of bronchiolitis – epidemiologic considerations. *Pediatr Res* 11: 239–243
44. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL (1981) Risk of respiratory syncytial virus infection for infants from low income families in relationship to age, sex, ethnic group, and maternal antibody level. *J Pediatr* 98: 708–715
45. Hall CB, Kopelman AE, Douglas RG, Geiman JM, Meagher MP (1979) Neonatal respiratory syncytial virus infection. *N Engl J Med* 300: 393–396
46. Hall CB, Douglas RG (1981) Modes of transmission of respiratory syncytial virus. *J Pediatr* 99: 100–103
47. Harte PG, Playfair JHL (1983) Failure of malaria vaccination in mice born to immune mothers. II. Induction of specific suppressor cells by maternal IgG. *Clin Exp Immunol* 51: 157–164
48. Henderson FW, Collier AM, Clyde WA, Denny FEW (1979). Respiratory syncytial virus infections, reinfections and immunity. *N Engl J Med* 300: 530–534
49. Hendry RM, Pierik LT, McIntosh K (1989) Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981–1987. *J Infect Dis* 160: 185–190
50. Holzhauser C (1978) Pinkengriep. Doctoral Thesis, University of Utrecht, Utrecht, The Netherlands
51. Hornsleth A, Bech-Thomsen N, Friis B (1985) Detection of RS-virus IgG-subclass-specific antibodies: variation according to age in infants and small children and diagnostic value in RS-virus-infected small infants. *J Med Virol* 16: 329–335
52. Hugli TE (1985) Structure and function of the anaphylatoxins. In: Müller-Eberhard HJ, Miescher PA (eds) *Complement*. Springer, Berlin Heidelberg New York Tokyo, pp 73–100
53. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG (1979) Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. *Am J Pathol* 97: 149–206
54. Ida S, Hooks JJ, Siraganian RP, Notkins AL (1977) Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon. *J Exp Med* 145: 892–906
55. Inaba Y, Tanaka Y, Omori T, Matumoto M (1970) Isolation of bovine respiratory syncytial virus. *Jpn J Exp Med* 40: 473
56. Jacobs JW, Edington N (1975) Experimental infection of calves with respiratory syncytial virus. *Res Vet Sci* 18: 299–306
57. Kasel JA, Walsh EE, Frank AL, Baxter BD, Taber LH, Glezen WP (1987/1988) Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. *Viral Immunol* 1: 199–205
58. Kaul TN, Welliver RC, Ogra PL (1982) Appearance of complement components and immunoglobulins on nasopharyngeal epithelial cells following naturally acquired infection with respiratory syncytial virus. *J Med Virol* 9: 149–158

59. Kaul TN, Faden H, Baker R, Ogra PL (1984) Virus-induced complement activation and neutrophil-mediated cytotoxicity against respiratory syncytial virus (RSV). *Clin Exp Immunol* 56: 501–508
60. Kennedy HE, Jones BV, Tucker EM, Ford NJ, Clarke SW, Furze J, Thomas LH, Stott EJ (1988) Production and characterization of bovine monoclonal antibodies to respiratory syncytial virus. *J Gen Virol* 69: 3023–3032
61. Key DW, Derbyshire JB (1984) Serological studies of parainfluenza type 3 virus, bovine adenovirus type 3 and bovine respiratory syncytial virus infection in beef calves. *Vet Microbiol* 9: 587–592
62. Kim HW, Leifkin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH (1976) Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. *Pediatr Res* 10: 75–78
63. Kimman TG, Zimmer GM, Straver PJ, de Leeuw P (1986) Diagnosis of bovine respiratory syncytial virus infections improved by virus detection in lung lavage samples. *Am J Vet Res* 47: 143–147
64. Kimman TG, Westenbrink F, Straver PJ, van Zaane D, Schreuder BEC (1987) Isotype-specific ELISAs for the detection of antibodies to bovine respiratory syncytial virus. *Res Vet Sci* 43: 180–187
65. Kimman TG, Westenbrink F, Schreuder BEC, Straver PJ (1987) Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies. *J Clin Microbiol* 25: 1097–1106
66. Kimman TG, Zimmer GM, Westenbrink F, Mars J, van Leeuwen E (1988) Epidemiological study of bovine respiratory syncytial virus infections in calves: influence of maternal antibodies on the outcome of disease. *Vet Rec* 124: 104–109
67. Kimman TG, Straver PJ, Zimmer GM (1989) Pathogenesis of naturally acquired bovine respiratory syncytial virus infection in calves: morphologic and serologic findings. *Am J Vet Res* 50: 684–693
68. Kimman TG, Terpstra GK, Daha MR, Westenbrink F (1989) Pathogenesis of naturally acquired bovine respiratory syncytial virus infection in calves: evidence for the involvement of complement and mast cell mediators. *Am J Vet Res* 50: 694–700
69. Kimman TG, Daha MR, Brinkhof JMA, Westenbrink F (1989) Activation of complement by bovine respiratory syncytial virus-infected cells. *Vet Immunol Immunopathol* 21: 311–325
70. Kimman TG, Westenbrink F, Straver PJ (1989) Priming for local and systemic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus, virus replication, route of administration and maternal antibodies. *Vet Immunol Immunopathol* 22: 145–160
71. Kimman TG, Sol J, Westenbrink F, Straver PJ (1989) A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine. *Vet Q* 11: 250–253
72. King AMQ, Stott EJ, Langer SJ, Young KK-Y, Ball LA, Wertz GW (1987) Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. *J Virol* 61: 2885–2890
73. Kingsburry DW, Bratt MA, Choppin PW, Hanson RP, Hosaka Y, Ter Meulen V, Norrby E, Plowright W, Rott R, Wunner WH (1978) Paramyxoviridae. *Intervirology* 10: 137–152
74. Krilov LR, Anderson LJ, Marcoux L, Bonagura VR, Wedgewood F (1989) Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. *J Infect Dis* 160: 777–782
75. Kumagai T, Wong DT, Ogra PL (1985) Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus. *Clin Exp Immunol* 61: 351–359

76. Lamprecht CL, Krause HE, Mufson MA (1976) Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. *J Infect Dis* 134: 211–217
77. Lerch RA, Stott EJ, Wertz GW (1989) Characterization of bovine respiratory syncytial virus proteins and mRNAs and generation of cDNAs clones to the viral mRNAs. *J Virol* 63: 833–840
78. Levine S, Klaiber-Franco R, Paradiso PR (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. *J Gen Virol* 69: 119–1239
79. Levine S, Dajani A, Klaiber-Franco R (1988) The response of infants with bronchiolitis to the proteins of respiratory syncytial virus. *J Gen Virol* 69: 1229–1239
80. Martin H (1967) Some considerations in dealing with respiratory disease in calves. *Vet Rec* 81: 255–261
81. Matumoto M, Inaba Y, Kutogi H, Sato K, Omori T, Goto Y, Hirose O (1974) Bovine respiratory syncytial virus: host range in laboratory animals and cell cultures. *Arch Ges Virusforsch* 44: 280–290
82. Mazanec MB, Nedrud JG, Lamm ME (1987) Immunoglobulin A monoclonal antibodies protect against Sendai virus. *J Virol* 61: 2624–2626
83. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM (1978) The immunological response to infection with respiratory syncytial virus in infants. *J Infect Dis* 138: 24–32
84. McIntosh K, McQuillin, Gardner PS (1979) Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection. *Infect Immun* 23: 276–281
85. McIntosh K, Fishaut JM (1980) Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus. *Prog Med Virol* 26: 94–118
86. McNulty MS, Bryson DG, Allan M (1983) Experimental respiratory syncytial virus pneumonia in young calves: microbiologic and immunofluorescent findings. *Am J Vet Res* 44: 1656–1659
87. Meurman O, Ruuskanen O, Sarkkinen H, Hanninen P, Halonen P (1984) Immunoglobulin class-specific antibody response in respiratory syncytial virus infection measured by enzyme immunoassay. *J Med Virol* 14: 67–72
88. Mills J, van Kirk JE, Wright PF, Chanock RM (1971) Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. *J Immunol* 107: 123–130
89. Mohanty SB, Lillie MG, Ingling AL (1976) Effect of serum and nasal neutralizing antibodies on respiratory syncytial virus infection in calves. *J Infect Dis* 134: 409–413
90. Morales F, Calder MA, Inglis JM, Murdoch PS, Williamson J (1983) A study of respiratory infections in the elderly to assess the role of respiratory syncytial virus. *J Infect* 7: 236–247
91. Morrison TG (1988) Structure, function and intracellular processing of paramyxovirus membrane proteins. *Virus Res* 10: 113–136
92. Mufson MA, Orvell C, Rafnar B, Norrby E (1985) Two distinct subtypes of human respiratory syncytial virus. *J Gen Virol* 66: 2111–2124
93. Mufson MA, Belshe RB, Orvell C, Norrby E (1987) Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. *J Clin Microbiol* 25: 1535–1539
94. Mufson MA, Belshe RB, Orvell C, Norrby E (1988) Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981–1986. *J Infect Dis* 157: 143–148
95. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM (1986) Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. *J Clin Microbiol* 24: 197–202

96. Murphy BR, Graham BS, Prince GA, Walsh EE, Chanock RM, Karzon DT, Wright PF (1986) Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. *J Clin Microbiol* 23: 1009–1014
97. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, Hemming VG, Rodriguez WJ, Kim HW, Graham BS, Wright PF (1986) Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. *J Clin Microbiol* 24: 894–898
98. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA (1988) Passive transfer of respiratory syncytial (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. *J Virol* 62: 3907–3910
99. Murphy BR, Walsh EE (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. *J Clin Microbiol* 26: 1595–1597
100. Nandapalan N, Taylor C, Scott R, Toms GL (1987) Mammary immunity in mothers of infants with respiratory syncytial virus infection. *J Med Virol* 22: 277–287
101. Nicholas JA, Mitchell MA, Lively ME, Rubino KL, Kinner JH, Harn NK, Smith CW (1988) Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus. *J Virol* 62: 4465–4473
102. Nicholas JA, Lively MA, Mitchell MA, Smith CW (1989) A 16-amino acid peptide of respiratory syncytial virus 1A protein contains two overlapping T cell-stimulating sites distinguishable by class II MHC restriction elements. *J Immunol* 143: 2790–2796
103. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S (1981) Maternal antibody and respiratory syncytial virus infection in infancy. *J Med Virol* 7: 263–271
104. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL (1986) Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. *Proc Natl Acad Sci USA* 83: 7462–7466
105. Olmsted RA, Collins PL (1989) The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species. *J Virol* 63: 2019–2029
106. Openshaw PJM, Pemberton RM, Ball LA, Wertz GW, Askonas BA (1988) Helper T cell recognition of respiratory syncytial virus in mice. *J Gen Virol* 69: 305–312
107. Orvell C, Norrby E, Mufson MA (1987) Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroups B. *J Gen Virol* 68: 3125–3135
108. Paccaud MF, Jacquier C (1970) A respiratory syncytial virus of bovine origin. *Arch Ges Virusforsch* 30: 327–342
109. Parrot RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM (1973) Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. *Am J Epidemiol* 98: 289–300
110. Pemberton RM, Cannon MJ, Openshaw PJM, Ball LA, Wertz GW, Askonas BA (1987) Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. *J Gen Virol* 68: 2177–2182
111. Pirier HM, Petrie L, Pringle CR, Allan EM, Kennedy GJ (1981) Acute fatal pneumonia in calves due to respiratory syncytial virus. *Vet Rec* 108: 411–416
112. Prince GA, Jenson AB, Horswood RL (1978) The pathogenesis of respiratory syncytial virus infection in cotton rats. *Am J Pathol* 93: 771–792

113. Prince GA, Potash L, Horswood RL, Camargo E, Suffin SC, Johnson RA, Chanock RM (1979) Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. *Infect Immun* 23: 723–728
114. Prince GA, Horswood RL, Koenig DW, Chanock RM (1985) Antigenic analysis of a putative new strain of respiratory syncytial virus. *J Infect Dis* 151: 634–637
115. Prince GA, Horswood RL, Chanock RM (1985) Quantitative aspects of immunity to respiratory syncytial virus infection in infant cotton rats. *J Virol* 55: 517–520
116. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM (1986) Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. *J Virol* 57: 721–728
117. Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM (1987) Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. *J Virol* 61: 1851–1854
118. Pringle CR (1987) Progress towards control of the acute respiratory viral diseases of childhood. *Bull WHO* 63: 133–137
119. Pullan CR, Toms GL, Martin AJ, Gardner PS, Webb JKG, Appleton DR (1980) Breast-feeding and respiratory syncytial virus infection. *Br Med J* 281: 1034–1036
120. Reiter J, Hutchings P, Lydyard PM, Cooke A (1986) Antibody-mediated modulation of the immune response. *Cell Immunol* 97: 91–101
121. Report to the Medical Research Council Subcommittee on respiratory syncytial virus vaccines (1978) *Br Med J* 2: 796–798
122. Richardson LS, Yolken RH, Belshie RB, Camargo E, Kim HW, Chanock RM (1978) Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. *Infect Immun* 20: 660–664
123. Richman AV, Pedreira FA, Tauraso NM (1971) Attempts to demonstrate hemagglutination and hemadsorption by respiratory syncytial virus. *Appl Microbiol* 21: 1099
124. Routledge EG, Willcocks MM, Morgan L, Samson ACR, Scott R, Toms GL (1987) Expression of the respiratory syncytial virus 22 k protein on the surface of infected HeLa cells. *J Gen Virol* 68: 1217–1222
125. Routledge EG, Willcocks MM, Samson ACR, Morgan L, Scott R, Anderson JJ, Toms GL (1988) The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. *J Gen Virol* 69: 293–303
126. Samson ACR, Willcocks MM, Routledge EG, Morgan LA, Toms GL (1986) A neutralizing monoclonal antibody to respiratory syncytial virus which binds to both F1 and F2 components of the fusion protein. *J Gen Virol* 67: 1479–1483
127. Scott R, DeLandazuri MO, Gardner PS, Own JJT (1976) Detection of antibody to respiratory syncytial virus by membrane fluorescence. *Clin Exp Immunol* 26: 78–85
128. Scott R, Kaul A, Scott M, Chiba Y, Ogra PL (1978) Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans. *J Infect Dis* 137: 810–817
129. Scott R, Scott M, Toms GL (1981) Cellular and antibody response to respiratory syncytial (RS) virus in human colostrum, maternal blood, and cord blood. *J Med Virol* 8: 55–66
130. Stewart RS, Gershwin LJ (1989) Role of IgE in the pathogenesis of bovine respiratory syncytial virus in sequential infections in vaccinated and nonvaccinated calves. *Am J Vet Res* 50: 349–355
131. Stott EJ, Thomas LH, Collins AP, Crough S, Jebbett J, Smith GS, Luther PD, Caswell R (1980) A survey of virus infections of the respiratory tract of cattle and their association with disease. *J Hyg* 85: 257–270

132. Stott EJ, Thomas LH, Taylor G, Collins AP, Jebbett J, Crough S (1984) A comparison of three vaccines against respiratory syncytial virus in calves. *J Hyg* 93: 251–261
133. Stott EJ, Taylor G (1985) Respiratory syncytial virus. Brief Review. *Arch Virol* 84: 1–52
134. Stott EJ, Ball LA, Young KK-Y, Furze J, Wertz GW (1986) Human respiratory syncytial virus glycoprotein expressed from a recombinant vaccinia virus vector protects mice against live virus challenge. *J Virol* 60: 607–613
135. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK-Y, King AMQ, Wertz GW (1987) Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. *J Virol* 61: 3855–3861
136. Stott EJ, Taylor G (1989) Immunity to respiratory syncytial virus. In: Dimmock NJ, Minor PD (eds) *Immune responses, virus infections and disease*. Oxford University Press, Oxford, pp 85–104
137. Taylor B, Wadsworth J, Golding J, Butler N (1982) Breast-feeding, bronchiolitis, and admissions for lower-respiratory illness and gastroenteritis during the first five years. *Lancet* i: 1227–1229
138. Taylor G, Stott EJ, Hughes M, Collins AP (1984) Respiratory syncytial virus infection in mice. *Infect Immun* 43: 649–655
139. Taylor G, Stott EJ, Bew M, Ferni BF, Cote PJ, Collins AP, Hughes M, Jebbet J (1984) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. *Immunology* 52: 137–142
140. Taylor G, Stott EJ, Hayle AJ (1985) Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus. *J Gen Virol* 66: 2533–2538
141. Taylor G, Stott EJ, Thomas LH (1987) Lymphocyte transformation responses of calves to respiratory syncytial virus. *J Med Virol* 22: 333–334
142. Thatcher EF, Gershwin LJ (1988) Generation and characterization of murine monoclonal antibodies specific for bovine immunoglobulin E. *Vet Immunol Immunopathol* 18: 53–66
143. Thomas LH, Stott EJ (1981) Diagnosis of respiratory syncytial virus infection in the bovine respiratory tract by immunofluorescence. *Vet Rec* 108: 432–435
144. Toms GL, Scott R (1987) Respiratory syncytial virus and the infant immune response. *Arch Dis Childhood* 62: 544–546
145. Treuhaft MW, Soukop JM, Sullivan BJ (1985) Practical recommendation for the detection of pediatric respiratory syncytial virus infection in infants. *Pediatrics* 72: 613–618
146. Trigo E, Liggitt HD, Evermann JF, Breeze RG, Huston LY, Silflow R (1985) Effect of in vitro inoculation of bovine respiratory syncytial virus on bovine pulmonary alveolar macrophage function. *Am J Vet Res* 46: 1098–1103
147. Trudel M, Nadon F, Seguin C, Ghobril S, Payment P, Trepanier P (1986) Immunovirological studies on human respiratory syncytial virus structural proteins. *Can J Microbiol* 32: 15–21
148. Trudel M, Nadon F, Seguin C, Dionne G, Lacroix M (1987) Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus. *J Gen Virol* 68: 2273–2280
149. Trudel M, Nadon F, Simard C, Belanger F, Alain R, Seguin C, Lussier G (1989) Comparison of caprine, human and bovine strains of respiratory syncytial virus. *Arch Virol* 107: 141–149
150. Trudel M, Nadon F, Seguin C, Simard C, Lussier G (1989) Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. *Vaccine* 7: 12–16

151. Tsutsumi H, Flanagan TD, Ogra PL (1987) Monoclonal antibodies to the large glycoprotein of respiratory syncytial virus: Possible evidence for several functional antigenic sites. *J Gen Virol* 68: 2161–2167
152. Tsutsumi H, Onuma M, Suga K, Honjo T, Chiba Y, Chiba S, Ogra PL (1988) Occurrence of respiratory syncytial virus subgroups A and B strains in Japan, 1980 to 1987. *J Clin Microbiol* 26: 1171–1174
153. Vainionpää R, Meurman O, Sarkinen H (1985) Antibody response to respiratory syncytial virus structural proteins in children with acute respiratory syncytial virus infection. *J Virol* 53: 976–979
154. Verhoeff J, Van Nieuwstadt APKMI (1984) BRS virus, PI3 virus and BHV1 infections of young stock on self-contained dairy farms: epidemiological and clinical findings. *Vet Rec* 114: 288–293
155. Vikerfors T, Grandien M, Olcen P (1987) Respiratory syncytial virus infections in adults. *Am Rev Respir Dis* 136: 561–564
156. Volovitz B, Welliver RC, Castro GD, Krystofik DA, Ogra PL (1988) The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. *Pediatr Res* 24: 504–507
157. Wagner DK, Graham BS, Wright PF, Walsh EE, Kim HW, Reimer CB, Nelson DL, Chanock RM, Murphy BR (1986) Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. *J Clin Microbiol* 24: 304–306
158. Wagner DK, Muelenaer P, Henderson FW, Snyder MH, Reimer CB, Walsh EE, Anderson LJ, Nelson DL, Murphy BR (1989) Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections. *J Clin Microbiol* 27: 589–592
159. Walsh EE, Hruska J (1983) Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. *J Virol* 47: 171–177
160. Walsh EE, Schlesinger JJ, Brandriss MW (1984) Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. *Infect Immun* 43: 756–758
161. Walsh EE, Cote PJ, Fernie BF, Schlesinger JJ, Brandriss MW (1986) Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. *J Gen Virol* 67: 505–513
162. Walsh EE, Hall CB, Briselli M, Brandriss MW, Schlesinger JJ (1987) Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. *J Infect Dis* 155: 1198–1204
163. Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P (1989) Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment protein. *J Gen Virol* 70: 2953–2961
164. Wang M-L, Skehal JJ, Wiley DC (1986) Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. *J Virol* 57: 124–128
165. Ward KA, Lambden PR, Ogilvie MM, Watt PJ (1983) Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. *J Gen Virol* 64: 1867–1876
166. Wellemans G (1977) Laboratory diagnosis methods for bovine respiratory syncytial virus. *Vet Sci Commun* 1: 179–198
167. Welliver RC, Kaul TN, Ogra PL (1979) Cell-mediated immune response to respiratory syncytial virus infection: relationship to the development of reactive airway disease. *J Pediatr* 94: 370–375
168. Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL (1980) The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. *J Pediatr* 96: 808–813

169. Welliver RC, Kaul TN, Sun M, Ogra PL (1984) Defective regulation of immune responses in respiratory syncytial virus infection. *J Immunol* 133: 1925–1930
170. Welliver RC (1988) Detection, pathogenesis, and therapy of respiratory syncytial virus infections. *Clin Microbiol Rev* 1: 27–39
171. Welliver RC, Sun M, Hildreth SW, Arumugham R, Ogra PL (1989) Respiratory syncytial virus-specific antibody responses in immunoglobulin A and E isotypes to the F and G proteins and to intact virus after natural infection. *J Clin Microbiol* 27: 295–299
172. Wertz GW, Stott EJ, Young KK-Y, Anderson K, Ball LA (1987) Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. *J Virol* 61: 293–301
173. Westenbrink F, Kimman TG (1987) Immunoglobulin M-specific enzyme-linked immunosorbent assay for serodiagnosis of bovine respiratory syncytial virus infections. *Am J Vet Res* 48: 1132–1137
174. Westenbrink F, Kimman TG, Brinkhof JMA (1989) Analysis of the antibody response to bovine respiratory syncytial virus proteins in calves. *J Gen Virol* 70: 591–601
175. Wong DT, Ogra PL (1986) Neonatal respiratory syncytial virus infection: role of transplacentally and breast milk-acquired antibodies. *J Virol* 57: 1203–1206
176. Zygraich N, Wellemans G (1981) Immunologic markers of an attenuated bovine respiratory syncytial (BRS) vaccine. *Zentralbl Veterinaermed [B]* 28: 355–362

Authors' address: Dr. T. G. Kimman, Central Veterinary Institute, Department of Virology, P.O. Box 365, NL-8200 AJ Lelystad, The Netherlands.

Received January 9, 1990